Home Compare BAYN.DE vs SAN.PA
Stock Comparison · Industry comparison · Drug Manufacturers - General

Bayer Aktiengesellschaft vs Sanofi: Which Stock Looks Stronger in 2026?

Sanofi holds the cleaner structural position, with the lead spread across growth and stability. Bayer Aktiengesellschaft still has the edge on valuation, which keeps the comparison from looking entirely one-sided. In the market, Bayer Aktiengesellschaft carries the stronger setup — intact trend against Sanofi's broken trend. That leaves a split case: the structural lead stays with Sanofi, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both growth and stability materially support the lead.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. BAYN.DE and SAN.PA share the same industry classification.

For a similarity-based comparison, see how Bayer Aktiengesellschaft and Sanofi each position within their functional peer groups in AssetNext.

Peer-Relative Score
BAYN.DE
Bayer Aktiengesellschaft
39
Peer-Score
Signal qualityHigh
vs
SAN.PA
Sanofi
46
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: BAYN.DE vs SAN.PA Profitability 16 16 Stability 28 67 Valuation 88 59 Growth 11 51 BAYN.DE SAN.PA
Gap Ranking
#1 Growth +40
#2 Stability +39
#3 Valuation +29
#4 Profitability
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BAYN.DE and SAN.PA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BAYN.DESAN.PA Relative valuation Structural strength

The price setup looks more supportive for Sanofi, but Bayer Aktiengesellschaft still has the stronger structure.

Valuation position uses Forward P/E and peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Sanofi is positioned higher in the group, while Bayer Aktiengesellschaft is closer to the middle.
Stability
On stability, Sanofi ranks near the top of the group; Bayer Aktiengesellschaft sits in the weaker half.
Growth — Dominant Gap
BAYN.DE
11
SAN.PA
51
Gap+40in favour of SAN.PA

One company is still expanding while the other is contracting, which creates a very wide growth split.

What keeps the gap from being one-sided

Valuation still leans toward Bayer Aktiengesellschaft, so the lead is real without reading as one-way.

What this means for the comparison

The lead is built on both growth and stability — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the BAYN.DE vs SAN.PA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how BAYN.DE and SAN.PA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.